Orion Pharma Solvency Measures Solvency measures show the firms balance between current assets and current liabilities. Net Working Capital: Net working capital = Current Assets (CA) – Current Liabilities (CL) All amounts are in BDT. Years 2010 2011 2012 2013 2014 Current Assets 229.86M 269.44M 232.82M 288.65M 289.70M Current Liabilities 338.36M 222.52M 214.08M 327.60M 522.97M Net Working Capital (CA – CL) -108.5.34M 46.92M 18.73M -38.95M -233.26M Orion Pharma’s NWC improved abrubtly in
Premium Generally Accepted Accounting Principles Balance sheet Asset
1. Historical Background: SQUARE today symbolizes a name – a state of mind. But its journey to the growth and prosperity has been no bed of roses. From the inception in 1958‚ it has today burgeoned into one of the top line conglomerates in Bangladesh. Square Pharmaceuticals Ltd.‚ the flagship company‚ is holding the strong leadership position in the pharmaceutical industry of Bangladesh since 1985 and is now on its way to becoming a high performance global player. SQUARE Pharmaceuticals Limited
Premium Pharmaceutical industry Pharmacology Limited company
Jim Mesplie MBA 519 – Competitive Strategy Case Analysis #4 FACTS Beginning as a small scale manufacturer of chemical in the United States‚ Merck Research Labs (MRL) became the top notch research institution in the pharmaceutical industry by World War II. By attracting the top talent in chemistry‚ biology‚ and pharmacology‚ MRL emerged as the leader in human pharmaceuticals with the release of highly necessary drugs to treat infections‚ and tuberculosis. MRL focused their strengths on three
Premium Generic drug Pharmacology Pharmaceutical industry
Omega Pharma is a Belgian company‚ located in Nazareth. It offers a wide range of high-quality prescription medicines‚ health products and cosmetics. With its 280 employees‚ Omega Pharma’s ultimate goal is to make people’s lives easier and better. The company was founded in 1987 by Marc Coucke and Yvan Vindevogel and made the news recently due to its acquisition in 2014 by the American company Perrigo. In the last eight years Omega Pharma managed to double its turnover and made the transition from
Premium Sociology Sociology New Zealand
PHARMA-SAYA INNOVATIVE SOLUTIONS‚ INC. Bringing better smiles that build better lives 259 CEU Bldg.‚ Sen. Gil Puyat Ave.‚ Makati City Phils. OUR MOTTO Bringing better smiles that build better lives. OUR MISSION-VISION STATEMENT PSIS is a Philippine company that values one of the most cognizant traits of the Filipino men‚ being gleeful‚ where the connotation that the SMILE is the most powerful weapon and shield of the Filipino started. The company is dedicated to bring better
Free Metro Manila Manila Toothpaste
Creating value‚ driving growth 3 7 th A N N U A L R E P O R T 2 0 0 9 - 2 0 1 0 37th ANNUAL REPORT 2009-10 Torrent Pharmaceuticals Limited 2 N TE CO N TS Corporate Information 02 Notice 03 Directors’ Report 06 Report on Corporate Governance 14 Auditors’ Report 24 Audited Financial Statements 28 Management Discussion and Analysis 55 Consolidated Financial Statements 66 37th ANNUAL REPORT 2009-10 3 CORPORATE INFORMATION DIRECTORS Sudhir Mehta Chairman REGISTERED
Premium Board of directors Corporate governance
SUN Pharma Company was established as a partnership firm by Dilip Sanghvi & his family to manufacture pharmaceutical formulations at Vapi‚ Gujarat. The Company specializes in selected therapeutic segment to psychiatry‚ cardiology‚ neurology‚ gastroenterology‚ orthopedics‚ ophthalmology nephrology and diabetology. It also makes Active Pharmaceutical Ingredients such as warfarin‚ carbamazepine‚ etodolac ‚ clorazepate‚ anticancers‚ steroids‚ peptides‚ sex hormones‚ and controlled substances. It is
Premium Pharmacology Pharmacology Ranbaxy Laboratories
constantly replenish the supply of potential blockbusters requires a consistent and dedicated approach to drug R&D. However no longer is inhouse research expertise sufficient. 2 Chart 1 Decreased R&D Productivity (source: FDA - PhRMA 2007) Pharma R&D Investments (Billion USD) 120 New medicines Approved by FDA 60 100 50 80 40 60 30 40 20 20 10 0 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 YEAR 0 To fill this pipeline gap‚ pharmaceutical
Premium Net present value Discounted cash flow Cash flow
1) Millenniums Pharmaceuticals strategy basically focused on revolutionizing drug development through the use of new technology during growth phase and making organizational changes during its maturing phase of by making strategic improvements in the organizational structure‚ making alliances‚ outsourcing etc by having vertical integration and moving from upstream to downstream model. In phase 1‚ technology helped the firm leapfrog most other biotechnology firms in the early stage of drug target
Premium Strategic management
Bio Pharma Case Analysis Question 1 How should BioPharma have used its production network in 2009? Should any of the plants have been idled? What is the annual cost of your proposal‚ including import duties? As Landgraf’s objective is to design a more cost-effective network (cost minimization problem subject to various capacity constraints)‚ the following production network in 2009 should have been used by BioPharma: *All numbers below are in millions *Total Transportation Cost=SUMPRODUCT
Premium Costs Total cost Variable cost